Raymond Anderson

ProRhythm, Inc. provides medical services. It developed HIFU (High Intensity Focused Ultrasound) for the treatment of atrial fibrillation (AF) a debilitating arrhythmia. The company was founded by David E. Acker in 1997 and is headquartered in Ronkonkoma, NY.

Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA.

Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA.

Fusion Medical Technologies, Inc. is used to develop, manufactures and market surgical hemostatic products like sutures and topical agents such as sponges which are used to stop bleeding in a variety of surgeries. The Company's product floSeal (R) matrix hemostatic sealant was used to control surgical bleeding. It products were used in a variety of surgical procedures like cardiac, vascular, spinal, ear, nose, throat, head, neck and cranial surgeries. The company marketed its products through direct sales force. It was headquartered in Fremont, CA.

Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA.

The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007.